Avalo Therapeutics Inc.

5.85
-0.74 (-11.23%)
At close: Apr 04, 2025, 3:59 PM
6.09
4.02%
After-hours: Apr 04, 2025, 05:45 PM EDT

Avalo Therapeutics Statistics

Share Statistics

Avalo Therapeutics has 10.67M shares outstanding. The number of shares has increased by 931.97% in one year.

Shares Outstanding 10.67M
Shares Change (YoY) 931.97%
Shares Change (QoQ) 1.99%
Owned by Institutions (%) 61.5%
Shares Floating 8.57M
Failed to Deliver (FTD) Shares 139.75K
FTD / Avg. Volume 186.54%

Short Selling Information

The latest short interest is 55.83K, so 0.53% of the outstanding shares have been sold short.

Short Interest 55.83K
Short % of Shares Out 0.53%
Short % of Float 0.66%
Short Ratio (days to cover) 0.41

Valuation Ratios

The PE ratio is -1.72 and the forward PE ratio is -1.71. Avalo Therapeutics's PEG ratio is 0.02.

PE Ratio -1.72
Forward PE -1.71
PS Ratio 136.95
Forward PS 4.8
PB Ratio 0.45
P/FCF Ratio -1.23
PEG Ratio 0.02
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Avalo Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 19.96, with a Debt / Equity ratio of 0.

Current Ratio 19.96
Quick Ratio 19.96
Debt / Equity 0
Debt / EBITDA -0.01
Debt / FCF -0.01
Interest Coverage -20.65

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $19.17K
Profits Per Employee $-1.53M
Employee Count 23
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 114K
Effective Tax Rate -0.33%

Stock Price Statistics

The stock price has increased by -58.96% in the last 52 weeks. The beta is 0.72, so Avalo Therapeutics's price volatility has been higher than the market average.

Beta 0.72
52-Week Price Change -58.96%
50-Day Moving Average 7.64
200-Day Moving Average 9.67
Relative Strength Index (RSI) 39.95
Average Volume (20 Days) 74.92K

Income Statement

In the last 12 months, Avalo Therapeutics had revenue of 441K and earned -35.13M in profits. Earnings per share was -4.32.

Revenue 441K
Gross Profit -26.83M
Operating Income -68.51M
Net Income -35.13M
EBITDA -68.51M
EBIT -31.7M
Earnings Per Share (EPS) -4.32
Full Income Statement

Balance Sheet

The company has 134.55M in cash and 568K in debt, giving a net cash position of 133.98M.

Cash & Cash Equivalents 134.55M
Total Debt 568K
Net Cash 133.98M
Retained Earnings -370.26M
Total Assets 150.73M
Working Capital 131.93M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -49.06M and capital expenditures 0, giving a free cash flow of -49.06M.

Operating Cash Flow -49.06M
Capital Expenditures 0
Free Cash Flow -49.06M
FCF Per Share -6.04
Full Cash Flow Statement

Margins

Gross margin is -6084.81%, with operating and profit margins of -15535.6% and -7965.76%.

Gross Margin -6084.81%
Operating Margin -15535.6%
Pretax Margin -7939.91%
Profit Margin -7965.76%
EBITDA Margin -15535.6%
EBIT Margin -15535.6%
FCF Margin -11123.81%

Dividends & Yields

AVTX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for AVTX is $35.5, which is 430.6% higher than the current price. The consensus rating is "Buy".

Price Target $35.5
Price Target Difference 430.6%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Stock Splits

The last stock split was on Dec 29, 2023. It was a backward split with a ratio of 1:240.

Last Split Date Dec 29, 2023
Split Type backward
Split Ratio 1:240

Scores

Altman Z-Score -0.6
Piotroski F-Score 1